ABILENE, Texas - November 9, 2022 - (Newswire.com)
Many say it's 'the most wonderful time of the year' and Chike Nutrition customers would have to agree. Chike Nutrition is ringing in the holidays and bringing cheer with the return of their most popular and requested seasonal flavor, Chike Mocha Mint Protein Iced Coffee. Although Chike Mocha Mint Protein Iced Coffee is available online starting Nov. 8 and in over 500 locations nationwide, it is sure to sell out quickly.
This flavor is refreshing, balanced and has a true chocolate mint flavor reminding you of that cookie in a silver sleeve. The smell of smooth mint hits first, followed by sweet chocolate notes with mint to balance, and a mid-level sweetness finish. Better yet, each serving is packed with 20 grams of non-GMO whey protein, 150mg of caffeine, and only 1 gram of sugar and 110 calories. A truly healthy option that doesn't compromise on taste.
A verified purchaser from last year named Heidi left a 5-star review stating, "This is the best flavor I've ever had. I need to stock up on 10 more bags since it's a limited edition flavor!!! I love it!!!!" Clearly, Chike Nutrition's customers are obsessed with Chike Mocha Mint Protein Iced Coffee.
Chike Mocha Mint Protein Iced Coffee takes the place of your sugary drive-thru coffee and is the ideal breakfast booster, healthy snack, or afternoon pick me-up. If you're looking for extra holiday cheer, adding Chike Mocha Mint protein coffee powder into recipes easily enhances delicious treats, making them a healthier choice.
"There's an extra layer of excitement from our customers this holiday season because of the return of our Chike Mocha Mint Protein Iced Coffee. We launched this seasonal flavor for the first time last year and we couldn't keep up with the demand. Since then, our customers have constantly made requests for it to be a permanent flavor, so much so that we made extra this year! Don't let an iced coffee drink during the cold weather keep you from trying Chike Mocha Mint Protein Iced Coffee. Grab a bag (or two) while you can and see what all of the hype is about. You won't be disappointed!", said Mac Mascorro, Brand Manager of Chike Nutrition.
It's time to put on your mittens and try this seasonal Protein Iced Coffee that is sure to bring you cheer!
###
About Chike Nutrition
Chike Nutrition is based in Abilene, Texas and proudly manufactures and produces all nine (and counting!) of their current flavors, ensuring the quality and consistency that Chike Nutrition demands in their products. You can find all of the flavors on Chike Nutrition's website and can follow new recipes, flavor launches, and more on Instagram and Pinterest. Learn more about Chike in their overview video.
Gb Sciences' anxiety formulations were previously identified using the company's AI-driven PhAROS™ platform, and they have now been evaluated using preclinical zebrafish models of stress at the National Research Council of Canada.
Gb Sciences, Inc. ("GbS"; OTCQB:GBLX), a leading plant-inspired research and biopharmaceutical drug development company, has received positive preclinical results in an interim report from its study using preclinical zebrafish models of stress at theNational Research Council of Canada (NRC). GbS' proprietary anxiety formulations have achieved a statistically significant reduction of stress in this preclinical study. The NRC is testing GbS' proprietary, psychotropic plant-based formulas for the treatment of depression and anxiety. GbS has leveraged its patent-pending PhAROS™ (Phytomedical Analytics for Research Optimization at Scale) platform to identify these combinations of plant compounds for novel drug candidates. These are the company's first non-cannabis formulations to advance in preclinical studies.
"We have achieved an important milestone in the development of our novel, kava-inspired anxiety formulations. Not only did some of our formulations achieve statistical significance in the animal model, but these minimum essential mixtures also demonstrated synergy by significantly outperforming the individual active ingredients within our minimum essential mixture formulations," said Dr. Andrea Small-Howard, Gb Sciences' President and Chief Science Officer. "This preclinical data also confirms that our PhAROS™ platform was capable of yielding concrete, potentially effective, plant-inspired combination drugs."
For these novel psychotropic drug candidates, the Gb Sciences research team used the PhAROS™ platform to identify new ingredients to improve upon an initial formulation for anxiety based on traditional medicine. The original plant mixture was derived from the kava plant, but some elements of kava are thought to cause liver toxicity. PhAROS™ identified ingredients from the Piper plant family as a substitute for the functionality of the ingredients in question without the potentially adverse safety profiles of those original ingredients. The Piper plant family includes pepper plants that are used worldwide in traditional medicines.
The PhAROSTM platform is a revolutionary, AI-driven science gateway and virtual research environment for drug discovery. With its data analytics and machine learning capabilities, PhAROS™ allows Gb Sciences to greatly reduce the time and money required to bring novel, plant-inspired formulations to market. PhAROS™ represents a breakthrough combination of data sciences and traditional plant-based medicines.
Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented, disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary, GbS Global Biopharma, Inc. The 'plant-inspired' active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences' intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences' lead program for Parkinson's disease is being prepared for a first-in-human clinical trial. Gb Sciences' formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council of Canada (NRC). The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences' productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects," "intends," "plans," "may," "could," "should," "anticipates," "likely," "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
